{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-25-000010","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.587208+00:00","generated_at":"2026-05-26T23:57:52.245610+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"iBio Q2 FY2025 net loss $4.4M; cash $7.2M; advances pipeline","bullets":["Revenue $0.2M; net loss $4.4M ($0.48/shr) vs $4.5M ($2.42/shr) prior year.","Cash & equivalents $7.2M as of Dec 31, 2024, including $0.2M restricted.","Discovered novel Activin E antibody; in-licensed anti-myostatin IBIO-600 in Jan 2025.","Initiated bispecific myostatin/activin A program; plans clinical investigation in 2026.","Board added David Arkowitz and António Parada; insider private placement closed Jan 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-25-000010","json":"https://secwatch.observer/filing/0001420720-25-000010.json","markdown":"https://secwatch.observer/filing/0001420720-25-000010.md","text":"https://secwatch.observer/filing/0001420720-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000010/0001420720-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000010/ibio-20250210x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:57:52.245610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}